Summary

Eligibility
for males ages 50 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Edward Uchio, MD

Description

Summary

Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.

Official Title

Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue in an Intermediate-Risk Patient Population

Keywords

Prostate Cancer, Prostate Tissue, NanoKnife System, Focal Therapy, Intermediate-Risk, Irreversible Electroporation (IRE), Prostatic Neoplasms, Irreversible Electroporation

Eligibility

You can join if…

Open to males ages 50 years and up

  1. Is greater than 50 years of age
  2. Has at least a 10-year life expectancy
  3. Has histologically confirmed organ-confined prostate cancer, clinical stage ≤ T2c
  4. Has a PSA ≤ 15 ng/mL or PSA density < 0.2 ng/mL2 if PSA is > 15 ng/mL
  5. Has Gleason score 3+4 or 4+3
  6. Has no evidence of extraprostatic extension by mpMRI
  7. Has no evidence of seminal vesicle invasion by mpMRI, and if suspected, confirmed by biopsy
  8. Physician is able to visualize prostate gland adequately on transrectal ultrasound imaging during enrollment evaluation
  9. Transperineal or transrectal targeted prostate biopsies of lesion, plus 10 core systematic biopsies to include adequate sampling of the peripheral zone correlating with an intermediate risk lesion in the area of the MR-visible lesion
  10. . A visible lesion on mpMRI that is accessible to Irreversible Electroporation (IRE) treatment (Note: A non-MRI visible lesion detected via systematic standard biopsy will not be considered an exclusion criterion provided the non-MRI visible lesion is singularly located in the contralateral hemisphere of the prostate; is Gleason 6; and comprises no more than 6 mm linear extent of prostate-bearing tissue in a single core on standard biopsy)
  11. . Has signed a written informed consent and in the judgment of the physician, the study is in the best interest of the subject
  12. . Understands and accepts the obligation and is logistically able to present for all scheduled follow-up visits

You CAN'T join if...

  1. Has known hypersensitivity to pancuronium bromide, atricurium or cisatricurium
  2. Is unfit for anesthesia or has a contraindication for agents listed for paralysis
  3. Has an active urinary tract infection (UTI)
  4. Has a history of bladder neck contracture
  5. Is interested in future fertility
  6. Has a history (within 3 years) of inflammatory bowel disease
  7. Has a concurrent major debilitating illness
  8. Had active treatment for a malignancy within 3 years, including malignant melanoma, except for prostate cancer or other types of skin cancer
  9. Has any active implanted electronic device (e.g., pacemaker)
  10. . Is unable to catheterize due to a urethral stricture disease
  11. . Has had prior or current prostate cancer therapies:
  12. Biologic therapy for prostate cancer
  13. Chemotherapy for prostate cancer
  14. Hormonal therapy for prostate cancer within three months of procedure
  15. Radiotherapy for prostate cancer
  16. Surgery for prostate cancer
  17. . Has had prior transurethral prostatectomy (TURP), stricture surgery, urethral stent or prostatic implants
  18. . Has had prior major rectal surgery (except hemorrhoids)
  19. . Is unfit for pelvic MRI scanning (e.g., severe claustrophobia, permanent cardiac pacemaker, metallic implants that are likely to contribute significant image artifacts, allergy or contraindication to gadolinium (to enhance MRI))
  20. . Is actively bleeding, is anticoagulated or on blood thinning medications, or has a bleeding disorder
  21. . Is a member of a vulnerable population such as prisoners, handicapped or mentally disabled persons, or economically or educationally disadvantaged persons
  22. . In the opinion of the treating physician, has a contraindication listed in the current NanoKnife System User Manual (section 2.3)

Locations

  • University of California Irvine accepting new patients
    Orange California 92868 United States
  • University of Colorado accepting new patients
    Aurora Colorado 80045 United States

Lead Scientist at UC Irvine

  • Edward Uchio, MD
    Clinical Professor, Urology, School of Medicine. Authored (or co-authored) 65 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Angiodynamics, Inc.
ID
NCT04972097
Study Type
Interventional
Participants
Expecting 118 study participants
Last Updated